Oral Ketamine as a Practical, Low-Cost Option for Severe Depression
Analysis Psychiatry / Psychopharmacology Hypothesis-generating Grade: Very Low
Andrade C
Aug 31, 2026 · Published in: The Journal of Clinical Psychiatry
Oral ketamine emerges as a safe, low-cost depression treatment.
Starting Regimen Predicts Early ADHD Treatment Instability in Adults
Analysis Psychiatry / Psychopharmacology Hypothesis-generating Grade: Low
Yonezawa N, Momo K
Aug 19, 2026 · Published in: Biological & Pharmaceutical Bulletin
ADHD treatment choice influences medication stability in Japanese adults.
Psilocybin Feasible for Treatment-Resistant Depression in NHS Setting
Analysis Psychiatry / Psychopharmacology Hypothesis-generating Grade: Low
Aug 7, 2026 · Published in: Nature Medicine
Psilocybin shows promise for treatment-resistant major depression.
Esketamine Reduces Depression in At-Risk Adolescents
Analysis Psychiatry / Psychopharmacology
Kosik-Gonzalez C, Fu DJ, Chen LN, et al.
Aug 1, 2026 · Published in: Focus (American Psychiatric Publishing)
Esketamine shows promise in quickly reducing severe depression in high-risk adolescents.
Network Meta-Analysis Ranks 21 Antidepressants for Acute Depression
Analysis Psychiatry / Psychopharmacology Practice-changing Grade: Moderate
Cipriani A, Furukawa TA, Salanti G, et al.
Aug 1, 2026 · Published in: Focus (American Psychiatric Publishing)
Antidepressants show varied efficacy and acceptability for major depressive disorder.
Dose-Specific Network Meta-Analysis Reaffirms Antipsychotics for Acute Mania
Analysis Psychiatry / Psychopharmacology Confirmatory Grade: Low
Fornaro M, Di Lorenzo C, Kishi T, et al.
Jul 29, 2026 · Published in: Journal of Affective Disorders
Risperidone tops the list for acute bipolar mania efficacy.
DISCARD Trial: Linear vs Hyperbolic Antidepressant Tapering Protocol
Analysis Psychiatry / Psychopharmacology Hypothesis-generating Grade: Very Low
Ostuzzi G, Gastaldon C, Zaccoletti D, et al.
Jul 16, 2026 · Published in: BMJ Open
Exploring safer ways to stop antidepressants in remitted depression.
Modeling Supports One-Day Oral Overlap for Aripiprazole LAI Start in Japan
Analysis Psychiatry / Psychopharmacology Confirmatory Grade: Low
Yamasaki Y, Sasaki T, Martinecz A, et al.
Jul 7, 2026 · Published in: Journal of Clinical Pharmacology
New aripiprazole regimen may enhance adherence in schizophrenia and bipolar I disorder.
Oral Prolonged-Release Ketamine Misses Primary Endpoint, Avoids Dissociation
Analysis Psychiatry / Psychopharmacology Hypothesis-generating Grade: Low
Walter M, Zu Eulenburg C, Damyanova A, et al.
Jun 1, 2026 · Published in: JAMA Network Open
Oral KET01 potentially offers safer, at-home depression treatment.
Esketamine Monotherapy Shows Rapid Efficacy in Treatment-Resistant Depression
Analysis Psychiatry / Psychopharmacology Confirmatory Grade: Moderate
Janik A, Qiu X, Lane R, et al.
Sep 1, 2025 · Published in: JAMA Psychiatry
Esketamine offers new hope for treatment-resistant depression monotherapy.
Fixed Low-Dose Oral Esketamine Fails in Treatment-Resistant Depression
Analysis Psychiatry / Psychopharmacology Inconclusive Grade: Low
Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, et al.
Sep 1, 2024 · Published in: Molecular Psychiatry
Oral esketamine may be effective only at higher doses for resistant depression.